Search Results - Michael D. Hogarty

Refine Results
  1. 1
    The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737

    The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737 by Mariana Boiani, Cristina K. Daniel, Xueyuan Liu, Michael D. Hogarty, Lawrence J. Marnett

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists

    Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists by Brian Lestini, Kelly C. Goldsmith, Mark Fluchel, Xueyuan Liu, Niel Chen, Bella Goyal, Bruce Pawel, Michael D. Hogarty

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma

    Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma by Laura D. Gamble, Michael D. Hogarty, Xueyuan Liu, David S. Ziegler, Glenn M. Marshall, Murray D. Norris, Michelle Haber

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

    Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma by Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma

    Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma by Kelly C. Goldsmith, Michelle Gross, Susan K. Peirce, Dema Luyindula, Xueyuan Liu, Annette Vu, Michael Sliozberg, Rong Guo, Huaqing Zhao, C. Patrick Reynolds, Michael D. Hogarty

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma

    Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma by Peter S. White, Paul M. Thompson, Takahiro Gotoh, Erin Okawa, Jun Igarashi, Marleen Kok, Cynthia Winter, Simon G. Gregory, Michael D. Hogarty, John M. Maris, Garrett M. Brodeur

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

    Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomis... by Pedro A. de Alarcón, Katherine K. Matthay, Wendy B. London, Arlene Naranjo, Sheena C. Tenney, Jessica A. Panzer, Michael D. Hogarty, Julie R. Park, John M. Maris, Susan L. Cohn

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation

    ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation by Guoliang Qing, Bo Li, Annette Vu, Nicolas Skuli, Zandra E. Walton, Xueyuan Liu, Patrick A. Mayes, David R. Wise, Craig B. Thompson, John M. Maris, Michael D. Hogarty, M. Celeste Simon

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas

    Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas by Olesya Chayka, Daisy Corvetta, Michael Dews, Alessandro E. Caccamo, Izabela Piotrowska, Giorgia Santilli, Sian Gibson, Neil J. Sebire, Nourredine Himoudi, Michael D. Hogarty, John Anderson, Saverio Bettuzzi, Andrei Thomas‐Tikhonenko, Arturo Sala

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Inhibition of the oncogenic fusion protein EWS-FLI1 causes G <sub>2</sub> -M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma

    Inhibition of the oncogenic fusion protein EWS-FLI1 causes G <sub>2</sub> -M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma by Stefan Zöllner, Saravana P. Selvanathan, Garrett T. Graham, Ryan Commins, Sung Hyeok Hong, Eric Moseley, Sydney E Parks, Jessica N. Haladyna, Hayriye V. Erkizan, Uta Dirksen, Michael D. Hogarty, Aykut Üren, Jeffrey A. Toretsky

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

    Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma by Mark Sausen, Rebecca Leary, Siân Jones, Jian Wu, C. Patrick Reynolds, Xueyuan Liu, Amanda L. Blackford, Giovanni Parmigiani, Luis A. Díaz, Nickolas Papadopoulos, Bert Vogelstein, Kenneth W. Kinzler, Victor E. Velculescu, Michael D. Hogarty

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project

    Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project by Elizabeth Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau‐Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael D. Hogarty, Arlene Naranjo, Samuel L. Volchenboum, Susan L. Cohn, Wendy B. London

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG

    Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG by Chizuko Okamatsu, Wendy B. London, Arlene Naranjo, Michael D. Hogarty, Julie M. Gastier‐Foster, A. Thomas Look, Michael P. LaQuaglia, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Robert C. Seeger, Tsutomu Saji, Hiroyuki Shimada

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

    Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group by Kevin Campbell, Julie M. Gastier‐Foster, Meegan Mann, Arlene Naranjo, Collin Van Ryn, Rochelle Bagatell, Katherine K. Matthay, Wendy B. London, Meredith S. Irwin, Hiroyuki Shimada, Meaghan Granger, Michael D. Hogarty, Julie R. Park, Steven G. DuBois

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

    ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma by Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe, Jin H. Park, Kateryna Krytska, Hannah T. Ryles, Marci Laudenslager, Eric Rappaport, Andrew Wood, Patrick McGrady, Michael D. Hogarty, Wendy B. London, Ravi Radhakrishnan, Mark A. Lemmon, Yaël P. Mossé

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression

    Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression by Vito Alessandro Lasorsa, Daniela Formicola, Piero Pignataro, Flora Cimmino, Francesco Maria Calabrese, Jaume Mora, Maria Rosaria Esposito, Marcella Pantile, Carlo Zanon, Marilena De Mariano, Luca Longo, Michael D. Hogarty, Carmen de Torres, Gian Paolo Tonini, Achille Iolascon, Mario Capasso

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group

    Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group by Larry Wang, Rie Suganuma, Naohiko Ikegaki, Xao X. Tang, Arlene Naranjo, Patrick McGrady, Wendy B. London, Michael D. Hogarty, Julie M. Gastier‐Foster, A. Thomas Look, Julie R. Park, John M. Maris, Susan L. Cohn, Robert C. Seeger, Hiroyuki Shimada

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study

    Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study by L L Wang, Risa Teshiba, Naohiko Ikegaki, Xiaochao Tang, Arlene Naranjo, Wendy B. London, Michael D. Hogarty, Julie M. Gastier‐Foster, A. Thomas Look, J R Park, John M. Maris, Susan L. Cohn, Robert C. Seeger, Shahab Asgharzadeh, Hiroyuki Shimada

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

    Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial by Michael D. Hogarty, David S. Ziegler, Andrea Franson, Yueh‐Yun Chi, Denice Tsao‐Wei, Kangning Liu, Rohan Vemu, Eugene W. Gerner, Elizabeth Bruckheimer, Anasheh Shamirian, Beth Hasenauer, Frank M. Balis, Susan Groshen, Murray D. Norris, Michelle Haber, Julie R. Park, Katherine K. Matthay, Araz Marachelian

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma

    Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma by Christina Coughlin, Mark D. Fleming, Richard G. Carroll, Bruce Pawel, Michael D. Hogarty, Xiaochuan Shan, Barbara A. Vance, Jarish N. Cohen, Sonya Jairaj, Elaina M. Lord, Michael H. Wexler, Gwenn-ael Danet-Desnoyers, Jack L. Pinkus, Geraldine S. Pinkus, John M. Maris, Stephan A. Grupp, Robert H. Vonderheide

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: